Member Login

 
Forgot password/Login issues?
Not a Member? Learn more.
  • Blog
  • Partnership
  • Contact
  • Cart (0)
  • Member Login
BCC Research
BCC Research
  • Member Login
  • Solution
    • Membership Membership
      • Academic
      • Corporate
    • Market Research
    • Custom Research
    • Company Index
    • Scorecard
  • Industries Industries
    • Life Sciences Life Sciences
      • Med Devices & Surgical
      • Cell Biology
      • Pharmaceuticals
      • Health Maintenance
    • Digital World Digital World
      • Instrumentation & Sensors
      • Safety and Security
      • Engineering
      • Photonics
      • Information Technology
    • Materials Materials
      • Advanced Materials
      • Plastics
      • Chemicals
      • Semiconductor
      • Nanotechnology
    • Energy & Sustainability Energy & Sustainability
      • Water-Membrane and Separations
      • Fuel Cell and Battery
      • Food
      • Energy
      • Manufacturing
      • Environment
  • Resources Resources
    • Blog
    • e-Course
    • Spotlights Library
    • Megatrends
    • Association Exclusives
    • Partnership
    • Market Research Studies
  • About
    • About BCC Research
    • Press Releases
    • Events
    • Careers
    • Contact
  • Beacon SearchBeacon Search

Or Ask your question to the BCC Research BEACON Beacon Research

  1. Company Index
  2. BioMarin
  3. News

BioMarin

  • Overview
  • Financial
  • In Reports
  • Products
  • History
  • News

In News

Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Momentum Stock - Yahoo Finance

Yahoo Finance - Jul 08, 2025

BioMarin inks $270M Inozyme buyout, bagging phase 3 prospect in first M&A move of the Sabry era - Fierce Biotech

Fierce Biotech - May 16, 2025

BioMarin Reports First Quarter 2025 Results and Reaffirms Full-year Guidance - PR Newswire

PR Newswire - May 01, 2025

BioMarin’s Roctavian Continues to Shine In Hemophilia A Despite Commercial Woes - insights.citeline.com

insights.citeline.com - Jul 04, 2025

BioMarin to buy rare disease drugmaker Inozyme for $270M - BioPharma Dive

BioPharma Dive - May 16, 2025

BioMarin agrees to acquire Inozyme for $270m - Pharmaceutical Technology

Pharmaceutical Technology - May 19, 2025

BioMarin Completes Acquisition of Inozyme Pharma for $270M - Contract Pharma

Contract Pharma - Jul 01, 2025

BioMarin stock rating initiated at Overweight by Morgan Stanley on Voxzogo growth - Investing.com

Investing.com - Jul 03, 2025

BioMarin Strengthens Rare Disease Pipeline with $270 Million Inozyme Acquisition - PharmExec

PharmExec - May 19, 2025

BioMarin grows enzyme portfolio with $270M Inozyme buy - FirstWord Pharma

FirstWord Pharma - May 16, 2025

BioMarin Acquires Inozyme for $270M, Gains Late-Stage Enzyme Therapy for Untreated Rare Disease - Stock Titan

Stock Titan - Jul 01, 2025

Jim Cramer on BioMarin: “I Don’t Think It Works Now” - Yahoo Finance

Yahoo Finance - Jun 15, 2025

BCC Research Beacon
Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Thank you for your interest in BCC Research. You will be added to our mailing list.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

Contact
  • 781-489-7301
  • info@bccresearch.com

© 2025 BCC Research

Privacy Policy |Site Map|Terms & Conditions

Please select categories of interest:

Check All